OBJECTIVES: To evaluate the pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis (CVVHD) after intravenous administration of unadjusted dosage regimens. PATIENTS AND METHODS: Two critically ill patients had eight blood samples collected during a 12 h interval on days 8 and 10 of polymyxin B therapy. Dialysate was collected every hour during the 12 h dosing interval. Polymyxin B binding in plasma was determined by rapid equilibrium dialysis. Concentrations of polymyxin B in plasma and dialysate samples were quantified using a validated ultra-performance liquid chromatography-tandem mass spectrometry assay. RESULTS: Respective maximum plasma concentrations in patients 1 and 2 were 8.62 and 4.38 mg/L; total body clearances (scaled linearly by body weight) were 0.043 and 0.027 L/h/kg, respectively, of which 12.2% and 5.62% were dialysis clearance, respectively. The corresponding volumes of distribution of polymyxin B at steady state were 0.50 and 0.34 L/kg, respectively, and protein binding in pooled plasma samples was 74.1% and 48.8%, respectively. CONCLUSIONS: Our findings indicate that the recommended polymyxin B doses should not be reduced for patients on CVVHD.
OBJECTIVES: To evaluate the pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis (CVVHD) after intravenous administration of unadjusted dosage regimens. PATIENTS AND METHODS: Two critically ill patients had eight blood samples collected during a 12 h interval on days 8 and 10 of polymyxin B therapy. Dialysate was collected every hour during the 12 h dosing interval. Polymyxin B binding in plasma was determined by rapid equilibrium dialysis. Concentrations of polymyxin B in plasma and dialysate samples were quantified using a validated ultra-performance liquid chromatography-tandem mass spectrometry assay. RESULTS: Respective maximum plasma concentrations in patients 1 and 2 were 8.62 and 4.38 mg/L; total body clearances (scaled linearly by body weight) were 0.043 and 0.027 L/h/kg, respectively, of which 12.2% and 5.62% were dialysis clearance, respectively. The corresponding volumes of distribution of polymyxin B at steady state were 0.50 and 0.34 L/kg, respectively, and protein binding in pooled plasma samples was 74.1% and 48.8%, respectively. CONCLUSIONS: Our findings indicate that the recommended polymyxin B doses should not be reduced for patients on CVVHD.
Authors: Brian C Nelson; Daniel P Eiras; Angela Gomez-Simmonds; Angela S Loo; Michael J Satlin; Stephen G Jenkins; Susan Whittier; David P Calfee; E Yoko Furuya; Christine J Kubin Journal: Antimicrob Agents Chemother Date: 2015-08-31 Impact factor: 5.191
Authors: Nikolas J Onufrak; Gauri G Rao; Alan Forrest; Jason M Pogue; Marc H Scheetz; Roger L Nation; Jian Li; Keith S Kaye Journal: Antimicrob Agents Chemother Date: 2017-04-24 Impact factor: 5.191
Authors: Gauri G Rao; Neang S Ly; Jürgen B Bulitta; Rachel L Soon; Marie D San Roman; Patricia N Holden; Cornelia B Landersdorfer; Roger L Nation; Jian Li; Alan Forrest; Brian T Tsuji Journal: J Antimicrob Chemother Date: 2016-08-03 Impact factor: 5.790
Authors: Zackery P Bulman; Neang S Ly; Justin R Lenhard; Patricia N Holden; Jürgen B Bulitta; Brian T Tsuji Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191
Authors: N M Smith; J R Lenhard; K R Boissonneault; C B Landersdorfer; J B Bulitta; P N Holden; A Forrest; R L Nation; J Li; B T Tsuji Journal: Clin Microbiol Infect Date: 2020-02-12 Impact factor: 8.067
Authors: Soon-Ee Cheah; Jian Li; Brian T Tsuji; Alan Forrest; Jürgen B Bulitta; Roger L Nation Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191